R&D | May 28, 2026
Novo Nordisk to showcase late-stage pipeline & semaglutide expansion at ADA 2026
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
The company is set to unveil new clinical data across obesity, diabetes, kidney, and liver disease programs
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
As per National Health Accounts (NHA) estimates, government health expenditure rose steadily between 2013-14 and 2022-23, while out-of-pocket spending declined significantly
For the full year, standalone gross revenue crossed Rs. 1,700 crore
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
The company highlighted continued demand strength and pricing resilience despite global disruptions
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
A one-shot gene-editing cholesterol therapy could soon be a reality
Fresh data from the State of the World’s Nursing 2025 report shows the global nursing workforce has expanded from 27.9 million in 2018 to 29.8 million in 2023
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
